Page 136 - Aet News Today

As pharmaceutical reps are used less and less, the role of the MSL has become more prominent as a conduit between life sciences companies and external stakeholders for drug development.

We live in a world in which the patient is empowered like never before. Think of how your interactions with the brands you love are different from 20 years ago across virtually every sector, from entertainment to transportation. We expect on-demand  services at the touch of a button – how we want it, when we want it. Yet clearly, the healthcare sector is lagging behind, especially in regard to putting the patient at the center of the experience and empowering them with easy and seamless ways...

Found for Business is an evidence-based obesity care program that prescribes 13 different medications (including GLP-1s) in 60 different combinations. It combines the medication with support from providers, coaching and an app that offers meal and activity tracking. 

NeuroFlow — a company that provides behavioral health integration software — struck a new partnership with Atlantic Health System, which will be using the company's technology across 16 ACO sites. The health system's goals for the partnership are to expand access to behavioral health professionals, alleviate administrative burden among primary care practices and improve performance in its ACO’s value-based contracts.

By incorporating elements of risk that complement a health system’s vision, healthcare leaders can drive a sustainable growth strategy that benefits patients and staff and better positions the organization for the future.

Moon Surgical recently raised $55.5 million for its robotic surgical assistant, which has earned regulatory clearance in the U.S. and European Union. The startup also appointed Fred Moll, founder of Intuitive Surgical and Auris Health, as independent chair of its board.

Individual market insurers are estimated to owe about $500 million in rebates to enrollees this year, a Kaiser Family Foundation analysis found. Small group market insurers are anticipated to owe about $330 million, and large group market insurers are expected to owe about $250 million.

Krystal Biotech’s Vyjuvek is approved to treat recessive and dominant forms of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. The redosable gene therapy, applied to the skin, delivers a gene that gets cells to produce collagen that DEB patients lack.

FDA approval of blockbuster AbbVie drug Rinvoq makes it the first oral therapy for moderately to severely active Crohn's disease. The regulatory nod is the seventh for the drug, which belongs to a class of therapies called JAK inhibitors.

Most employers are looking to maintain their investments in wellbeing programs, according to a survey from Fidelity Investments and the Business Group on Health. However, some areas of wellbeing will be emphasized more than others.